Member Info for Lionel1

Genedrive May directly benefit from this .

https://www.nihr.ac.uk/news/nihr-welcomes-300m-investment-into-clinical-trials-infrastructure-bringing-new-medicines-to-patients-across-the-uk/36590

The person left was Alastair Haigh.

@Roger , Calm down .. RNR1 and Cyp2c19 ID kit will be soon routine testing in NHS , If you are an investor buy more and sit back., this will come good . This board has become kids playground and so much nonsense being spread . You change your tune everyday :-) . I wonder where do you get time to type all those long comments . I like your English though as I am non English speaker .

Https://cpe.org.uk/our-news/implementing-pharmacogenetics-in-the-nhs-help-design-the-optimal-service/

FYI , That’s NHS website not Genedrive’s

@Slacker , Now Shu**p and F****f

Exploring rapid testing

NICE recommends laboratory testing where possible, but is also supportive of a POCT that Dr McDermott and his team have been involved in developing that could help the NHS implement this new guidance more quickly.

“[Our group has] been involved in the development and validation of different rapid point-of-care tests,” Dr McDermott explains. “With a company called Genedrive, here in Manchester, we’ve developed a test where you take a cheek swab and put it into a machine and it will produce a result to help guide anti-platelet therapy within an hour. It’s a really exciting development that we’ve just finished validating and the results are extremely impressive.”

Such rapid testing has many advantages, including being able to offer alternative treatments to patients much sooner and easing pressures on the wider healthcare system.

“[It is estimated that patients who have adverse drug reactions] take up around 8,000 hospital beds at any one time and the costs to the NHS are measured in billions. So even small improvements in the safety and effectiveness of medicines could have a significant impact on the healthcare system as a whole. Medicines working well are good for patients, but also good for health systems since it means people get better quicker and can potentially be discharged quicker.”

Https://www.linkedin.com/posts/genomics-education-programme_icymi-activity-7235255281050374144-ApEq?utm_source=share&utm_medium=member_ios

https://www.genomicseducation.hee.nhs.uk/blog/nice-approves-genomic-test-to-prevent-secondary-strokes/

Lol Stephen , I would do the same..

GDR machines in this video ??

https://youtu.be/0P8mYJoH-O0?si=aDJNJsV-M0QFU7N1

See if this helps ..View coA’s

https://www.genedrive.com/assays/mt-rnr1-documentation.php

Lol Gloria , I use AI but That wasn’t me :-)

Which one of you done this ?? Own it :-)

https://www.reddit.com/r/pennystocks/comments/1f2o5c3/genedrive_ticker_gdr_london_stock/

This will help companies like Genedrive .

https://www.gov.uk/government/news/uk-secures-400-million-investment-to-boost-clinical-trials

Https://www.sagentiainnovation.com/case-studies/genedrive-point-of-need-molecular-diagnostics-sample-preparation/

Https://www.eventbrite.co.uk/e/health-innovation-east-midlands-polypharmacy-community-of-practice-tickets-910652896327?

Thanks Eureka ,

This is from a recent article .

“The issue here is one of capacity. As the NICE guidance suggests, the NHS doesn’t currently have enough clinical scientists to run the tests. The genomics workforce is set to expand over the next three to five years as part of the ‘NHS long-term workforce plan’, but in the meantime, clinicians will meet demand with second-choice POCTs, if the other option is no test at all.”

If anyone interested..

https://us02web.zoom.us/webinar/register/WN_z6y8IK8fSTWzXnKuM4cz_Q#/registration

@Hang , somebody already cleared this yesterday and yet again you posting nonsense , Kelliop is the company with 1 or 2 people and they have a basic MT RNR1 test which has no comparison with Genedrive test , There is no information about Kelliop accuracy or speed , they are just doing a pilot in a children’s hospital, and GDR MT RNR1 test being used in several Hospitals across UK and Europe.

The Genedrive MT-RNR1 ID Kit is a well-regarded test for detecting the MT-RNR1 m.1555A>G gene variant, which helps prevent antibiotic-induced hearing loss in newborns. It is a rapid, point-of-care test that provides results in 26 minutes with 100% sensitivity and specificity. The test has been recommended by NICE for use in the NHS, and its implementation has shown to be effective without disrupting clinical practice. There is no information available about a "Kelliop MT RNR1 test," suggesting it may not be a recognized or comparable alternative to the Genedrive test.

I think Genedrive CEO said about Mayo clinic , Kelliop is not even a proper company , it is just one persons idea , it takes years to commercially available .. have to go through so many hurdles ..

https://www.linkedin.com/company/kelliop/

Yes I was also hoping to get Lamborghini later this year .

I have seen this couple of months ago , GDR kit takes only 26 mins and the US kit takes more than 50 mins , time is crustal in golden hour , They are doing a pilot programme now , they are in the same stage where GDR was in 2018 , it takes atleast 5 years from now to get the kit into the market .